{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "NOK", "esgPopulated": false, "market": "no_market", "longName": "Lytix Biopharma AS", "marketState": "REGULAR", "regularMarketPrice": 9.75, "messageBoardId": "finmb_30221892", "exchange": "OSL", "shortName": "LYTIX BIOPHARMA AS", "exchangeTimezoneShortName": "CEST", "exchangeTimezoneName": "Europe/Oslo", "regularMarketChangePercent": -2.5, "gmtOffSetMilliseconds": 7200000, "fiftyTwoWeekLowChange": 3.75, "fiftyTwoWeekLowChangePercent": 0.625, "fiftyTwoWeekRange": "6.0 - 13.0", "fiftyTwoWeekHighChange": -3.25, "fiftyTwoWeekHighChangePercent": -0.25, "fiftyTwoWeekLow": 6.0, "fiftyTwoWeekHigh": 13.0, "earningsTimestamp": 1645102800, "earningsTimestampStart": 1645102800, "earningsTimestampEnd": 1645102800, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.13, "firstTradeDateMilliseconds": 1623654000000, "priceHint": 2, "regularMarketChange": -0.25, "regularMarketTime": 1684137511, "regularMarketDayHigh": 10.0, "regularMarketDayRange": "9.5 - 10.0", "regularMarketDayLow": 9.5, "regularMarketVolume": 17671, "regularMarketPreviousClose": 10.0, "bid": 9.5, "ask": 9.8, "fullExchangeName": "Oslo", "financialCurrency": "NOK", "regularMarketOpen": 10.0, "averageDailyVolume3Month": 26495, "averageDailyVolume10Day": 74269, "sharesOutstanding": 40068300, "bookValue": 3.372, "fiftyDayAverage": 7.2886, "fiftyDayAverageChange": 2.4614, "fiftyDayAverageChangePercent": 0.33770546, "twoHundredDayAverage": 8.0555, "twoHundredDayAverageChange": 1.6945, "twoHundredDayAverageChangePercent": 0.21035317, "marketCap": 390665920, "priceToBook": 2.891459, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "symbol": "LYTIX.OL"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Sandakerveien 138", "city": "Oslo", "zip": "0484", "country": "Norway", "website": "https://www.lytixbiopharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products also include LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. The company was incorporated in 2003 and is based in Oslo, Norway.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Oystein  Rekdal Ph.D.", "title": "Co-Founder & CEO", "fiscalYear": 2022, "totalPay": {"raw": 4109000, "fmt": "4.11M", "longFmt": "4,109,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Gjest  Breistein M.Sc.", "title": "Chief Financial Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Gry  Stensrud Ph.D.", "age": 52, "title": "Chief Technology Officer", "yearBorn": 1970, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Baldur  Sveinbj\u00f8rnsson Ph.D.", "title": "Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Graeme  Currie Ph.D.", "title": "Chief Devel. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Stephen T. Worsley MBA", "age": 59, "title": "Chief Bus. Officer", "yearBorn": 1963, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ole Peter Nordby", "title": "Head of IR & Communication Mang.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Jacqueline  Earabino", "title": "Head of Clinical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}